CHA ÀÇ°úÇдëÇб³ Â÷º´¿ø professor

±³¼ö´Ô»çÁø
  • Àå¼öÁø
  • ÇÙÀÇÇаúÀå
    Áø·áÇù·Â¼¾ÅÍ ¼ÒÀå
  • ¼Ò ¼Ó: ºÐ´çÂ÷º´¿ø ÇÙÀÇÇаú
  • Àü¹®ºÐ¾ß : ÇÙÀÇÇÐü³»°Ë»ç, Á¾¾çÇÙÀÇÇÐ, ³ú½Å°æÇÙÀÇÇÐ, ½ÉÀåÇÙÀÇÇÐ, ÇÙÀÇÇÐÄ¡·á
  • Á÷ À§: ºÎ±³¼ö(ÇÙÀÇÇаúÀå,Áø·áÇù·Â¼¾ÅÍ ¼ÒÀå)
  • ¸Þ ÀÏ: ºñ°ø°³
  • Àü È­: 1577-4488
  • ÆÑ ½º:
  • ÁÖ ¼Ò: °æ±âµµ ¼º³²½Ã ºÐ´ç±¸ ¾ßž·Î 59
  • ȨÆäÀÌÁö:
  • ·Î±×ÀÎ

ÅǸ޴º

ÁÖ¿ä¹ßÇ¥³í¹®

ÁÖ¿ä¹ßÇ¥³í¹®
¹øÈ£ ±¸ºÐ Á¦¸ñ
45 (±¹¿Ü)SCI Comparison of Recombinant Human Thyroid-Stimulating Hormone and Thyroid Hormone Withdrawal for 131I Therapy in Patients With Intermediate- to High-Risk Thyroid Cancer A Systematic Review and Meta-analysis
44 (±¹¿Ü)SCI Clinical Implications of Adding SPECT/CT to RadioiodineWhole-Body Scan in Patients With Differentiated Thyroid Cancer A systematic review and meta-analysis
43 (±¹¿Ü)SCI The Diagnostic Value of F-18 FDG PET/CT in Differentiated Thyroid Cancer Patients with Elevated Thyroglobulin/Thyroglobulin Antibody Levels and Negative Iodine Scintigraphy: A Systematic Review and Meta-analysis
42 (±¹¿Ü)SCI Peritoneal and Nodal Gliomatosis Mimicking Metastasis on FDGPET/CT in a Patient With Ovarian Immature Teratoma
41 (±¹¿Ü)SCI Safety and Efficacy of Allogeneic Umbilical Cord Blood Therapy for Global Development Delay and Intellectual Disability
40 (±¹¿Ü)SCIE Diagnostic value of ¥á-synuclein seeding amplification assays in ¥á-synucleinopathies: A systematic review and meta-analysis
39 (±¹¿Ü)SCI Prognostic significance of liver CT-attenuation and 18 F-FDG uptake for predicting hepatic recurrence following curative resection of colorectal cancer
38 (±¹¿Ü)SCI "Second primary malignancy risk in thyroid cancer and matched patients with and without radioiodine therapy analysis from the observational health data sciences and informatics"
37 (±¹¿Ü)SCIE "Diagnostic performance of 18F?FDG PET or PET/CT in differential diagnosis of uterine leiomyomas and uterine sarcomas: systematic review and meta?analysis of the literature"
36 (±¹¿Ü)SCIE NOX2-Induced High Glycolytic Activity Contributes to the Gain of COL5A1-Mediated Mesenchymal Phenotype in GBM
ÀÌÀüÆäÀÌÁö À̵¿ 1 2 3 4 5 ´ÙÀ½ÆäÀÌÁö À̵¿
Copyright ¨Ï chamc, All rights reserved.

ºü¸£°í Æí¸®ÇÑ ÀÎÅÍ³Ý Áø·á¿¹¾à

  • °­³²Â÷º´¿ø
  • ºÐ´çÂ÷º´¿ø
  • ºÐ´çÂ÷¿©¼ºº´¿ø
  • ±¸¹ÌÂ÷º´¿ø
  • ¿©¼ºÀÇÇבּ¸¼Ò
  • Â÷¿ò

ÀüÈ­¹®ÀÇ

  • °­³²Â÷º´¿ø 02.3468.3000
  • ºÐ´çÂ÷º´¿ø 031.780.5000
  • Â÷¿ò 02.3015.5300
  • ±¸¹ÌÂ÷º´¿ø 054.450.9700
  • ´ë±¸¿©¼ºÂ÷º´¿ø 02.222.4200
  • °­³²°ÇÁø¼¾ÅÍ 02.2191.3900
  • ºÐ´çÁ¾ÇÕ°Ç°­ÁõÁø¼¾ÅÍ 031.780.5940
  • ½ºÆ÷·º½º °ÇÁø¼¾ÅÍ 02.3473.2111
  • ±¸¹ÌÂ÷º´¿ø°ÇÁø¼¾ÅÍ 054.450.9800
  • ȨÆäÀÌÁö°ü¸®ÀÚ 031.780.1729